Scancell Holdings Plc Director Dealing (7814P)
February 19 2021 - 10:00AM
UK Regulatory
TIDMSCLP
RNS Number : 7814P
Scancell Holdings Plc
19 February 2021
19 February 2021
Scancell Holdings plc
("Scancell" or the "Company")
Director Dealing
Scancell Holdings plc (AIM: SCLP), the developer of novel
immunotherapies for the treatment of cancer and infectious disease,
announces that Vulpes Life Sciences Fund ("Vulpes"), a person
closely associated with Martin Diggle, Non-Executive Director, has
sold 400,000 ordinary shares of 0.1 pence each in Scancell Holdings
plc ("Ordinary Shares") at an aggregated price of 27.25 pence per
Ordinary Share.
Following the sale of Ordinary Shares, Vulpes has a total
interest of 116,179,029 shares representing 14.3% of the total
voting rights of the Company.
For further information, please contact:
Scancell Holdings plc +44 (0) 20 3727 1000
Dr John Chiplin, Executive Chairman
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited +44 (0) 20 7886 2500
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
FTI Consulting +44 (0) 20 3727 1000
Simon Conway/Natalie Garland-Collins
About Scancell
Scancell is developing novel immunotherapies for the treatment
of cancer based on its technology platforms, ImmunoBody(R) ,
Moditope(R) and AvidiMab(TM) , with four products in multiple
cancer indications and development of a vaccine for COVID-19.
ImmunoBody(R) vaccines target dendritic cells and stimulate both
CD4 and CD8 T cells with the ability to identify, target and
eliminate cancer cells. These cancer vaccines have the potential to
be used as monotherapy or in combination with checkpoint inhibitors
and other agents. The Directors believe that this platform has the
potential to enhance tumour destruction, prevent disease recurrence
and extend survival.
-- SCIB1, Scancell's lead product, is being developed for the
treatment of metastatic melanoma. In a Phase 1/2 clinical trial,
survival with SCIB1 treatment appears superior to historical
survival rates, with 14 of 16 resected patients receiving 2-4 mg
doses of SCIB1 surviving for more than five years (as reported in
February 2018).
-- SCIB2 is being developed for the treatment of non-small cell
lung cancer and other solid tumours.
DNA vaccine against COVID-19: As research data emerges, it is
becoming increasingly clear that the induction of potent and
activated T cells may play a critical role in the development of
long-term immunity and clearance of virus-infected cells. Initial
research is underway and Scancell anticipates initiating a Phase 1
clinical trial known as COVIDITY during 2021.
Moditope(R) represents a completely new class of potent and
selective immunotherapy agents based on stress-induced
post-translational modifications (siPTM). Examples of such
modifications are citrullination, an enzyme-based conversion of
arginine to citrulline, and homocitrullination (or carbamylation),
in which lysine residues are converted to homocitrulline.
Expression of peptides containing these modifications have been
demonstrated to induce potent CD4 cytotoxic t cells to eliminate
cancer. Previous pre-clinical studies have demonstrated that
conjugation of these Moditope(R) peptides to Amplivant(R) enhances
anti-tumour immune responses 10-100 fold and resulted in highly
efficient tumour eradication, including protection against tumour
recurrence.
-- Modi-1 consists of two citrullinated vimentin peptides and
one citrullinated enolase peptide each conjugated to Amplivant(R) .
Vimentin and enolase peptides are highly expressed in triple
negative breast, ovarian, head and neck, and renal cancer, as well
as many other cancers. The Company continues to progress the Modi-1
Phase 1/2 clinical trial for regulatory submission to start the
planned clinical study in the UK in the first half of 2021.
AvidiMab(TM) has broad potential to increase the avidity or
potency of any therapeutic monoclonal antibody (mAb) including
those being developed for autoimmune diseases, as well as cancer.
Scancell's development pipeline includes mAbs against specific
tumour-associated glycans (TaGs) with superior affinity and
selectivity profiles, that have now been further engineered using
the Company's AvidiMab(TM) technology; this confers the Scancell
anti-TaG mAbs with the ability to directly kill tumour cells. The
Company has entered into three non-exclusive research agreements
with leading antibody technology companies to evaluate the
Company's anti-TaG mAbs including those enhanced with the
AvidiMab(TM) technology.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH
THEM
Details of the person discharging managerial responsibilities/person
1 closely associated
a) Name Martin Diggle
------------------------------- -------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Person closely associated with Vulpes Life
Science Fund
------------------------------- -------------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Scancell Holdings plc
------------------------------- -------------------------------------------
b) LEI 2138008RXEG856SNP666
------------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
----------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1 pence each
financial instrument,
type of instrument
------------------------------- -------------------------------------------
b) Identification Code GB00B63D3314
------------------------------- -------------------------------------------
c) Nature of the transaction Sale of shares
------------------------------- -------------------------------------------
d) Price(s) and volume(s) 200,000 ordinary shares at 27 pence per
ordinary share;
200,000 ordinary shares at 27.5 pence per
ordinary share;
------------------------------- -------------------------------------------
e) Aggregated information 400,000 Ordinary Shares
- Aggregated volume 27.25 pence per Ordinary Share
- Aggregated price
------------------------------- -------------------------------------------
f) Date of the transaction 18 February 2021
------------------------------- -------------------------------------------
g) Place of the transaction London Stock Exchange, AIM
------------------------------- -------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEALANFSNFEFA
(END) Dow Jones Newswires
February 19, 2021 10:00 ET (15:00 GMT)
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2024 to May 2024
Scancell (LSE:SCLP)
Historical Stock Chart
From May 2023 to May 2024